TickerFacts.

Aura Biosciences, Inc. (AURA): Total Liabilities

Annual figures by period end, from SEC filings.

$32.52M
As of 2025-12-31
$32.86M
As of 2026-06-30
+4.7%
3-year compound annual growth
+64.0%
5-year compound annual growth
2020-12-31: $2.74M2021-12-31: $7.71M2022-12-31: $28.35M2023-12-31: $29.23M2024-12-31: $30.53M2025-12-31: $32.52M$32.52M
2020-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$32.52M+6.5%2026-03-30, Balance as of period end
2024-12-31$30.53M+4.5%2026-03-30, Balance as of period end
2023-12-31$29.23M+3.1%2025-03-24, Balance as of period end
2022-12-31$28.35M+267.5%2024-03-27, Balance as of period end
2021-12-31$7.71M+181.5%2023-03-15, Balance as of period end
2020-12-31$2.74Mn/a2022-03-23, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Aura Biosciences, Inc. (AURA)2025-12-31$32.52M+6.5%
SAB Biotherapeutics, Inc. (SABS)2025-12-31$21.32M+17.0%
Sutro Biopharma, Inc. (STRO)2025-12-31$306.28M-10.6%
Cabaletta Bio, Inc. (CABA)2025-12-31$53.03M+62.1%
Caribou Biosciences, Inc. (CRBU)2025-12-31$53.19M-11.9%
Inhibikase Therapeutics, Inc. (IKT)2025-12-31$8.30M+122.3%
Precision Biosciences Inc (DTIL)2025-12-31$62.17M-22.3%
Vaxart, Inc. (VXRT)2025-12-31$98.28M-8.5%
Editas Medicine, Inc. (EDIT)2025-12-31$159.25M-23.2%

Compare AURA, SABS, STRO, CABA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗